These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29298276)

  • 1. Targeted therapies and outcomes data: the inflammatory hypothesis matures.
    Sharan L; Krasuski RA
    Curr Opin Lipidol; 2018 Feb; 29(1):56-57. PubMed ID: 29298276
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytokines as therapeutic targets for cardio- and cerebrovascular diseases.
    Liberale L; Ministrini S; Carbone F; Camici GG; Montecucco F
    Basic Res Cardiol; 2021 Mar; 116(1):23. PubMed ID: 33770265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colchicine in coronary disease: another renaissance of an ancient drug.
    Fiolet ATL; Thompson PL; Mosterd A
    Cardiovasc Res; 2021 Jan; 117(1):e4-e6. PubMed ID: 33426561
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-inflammatory Strategies to Prevent Diabetic Cardiovascular Disease.
    Jialal I; Devaraj S
    Clin Pharmacol Ther; 2015 Aug; 98(2):121-3. PubMed ID: 25732108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation and CVD in 2017: From clonal haematopoiesis to the CANTOS trial.
    Swirski FK
    Nat Rev Cardiol; 2018 Feb; 15(2):79-80. PubMed ID: 29263444
    [No Abstract]   [Full Text] [Related]  

  • 6. Lipid oxidation and cardiovascular disease: introduction to a review series.
    McIntyre TM; Hazen SL
    Circ Res; 2010 Nov; 107(10):1167-9. PubMed ID: 21071714
    [No Abstract]   [Full Text] [Related]  

  • 7. Biologics and Cardiovascular Disease.
    Van Taunay JS; Albelda MT; Frias JC; Lipinski MJ
    J Cardiovasc Pharmacol; 2018 Aug; 72(2):77-85. PubMed ID: 29738370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential use of the pregnane X receptor in cardiovascular therapy.
    Swales KE; Bishop-Bailey D
    Expert Rev Cardiovasc Ther; 2012 Sep; 10(9):1079-82. PubMed ID: 23098141
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-inflammatory Treatment for Seemingly Non-inflammatory Disorders. Editorial.
    Maru Y
    Endocr Metab Immune Disord Drug Targets; 2015; 15(2):82. PubMed ID: 26004772
    [No Abstract]   [Full Text] [Related]  

  • 10. Endothelial Cells: From Dysfunction Mechanism to Pharmacological Effect in Cardiovascular Disease.
    Haybar H; Shahrabi S; Rezaeeyan H; Shirzad R; Saki N
    Cardiovasc Toxicol; 2019 Feb; 19(1):13-22. PubMed ID: 30506414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the immune response in atherosclerosis: It's time for clinical trials!
    Joffre J; Ait-Oufella H
    Arch Cardiovasc Dis; 2017 Dec; 110(12):643-645. PubMed ID: 29051009
    [No Abstract]   [Full Text] [Related]  

  • 12. Inflammation modulation and cardiovascular disease prevention.
    Awan Z; Genest J
    Eur J Prev Cardiol; 2015 Jun; 22(6):719-33. PubMed ID: 24711609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-17 inhibition in psoriatic arthritis.
    Boyd T; Kavanaugh A
    Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S119-23. PubMed ID: 26471234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel anti-inflammatory therapies for the treatment of atherosclerosis.
    Khan R; Spagnoli V; Tardif JC; L'Allier PL
    Atherosclerosis; 2015 Jun; 240(2):497-509. PubMed ID: 25917947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials.
    Passacquale G; Di Giosia P; Ferro A
    Cardiovasc Res; 2016 Jan; 109(1):9-23. PubMed ID: 26410367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword.
    Simons KH; de Jong A; Jukema JW; de Vries MR; Arens R; Quax PHA
    Nat Rev Cardiol; 2019 Jun; 16(6):325-343. PubMed ID: 30770894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resolvins as proresolving inflammatory mediators in cardiovascular disease.
    Capó X; Martorell M; Busquets-Cortés C; Tejada S; Tur JA; Pons A; Sureda A
    Eur J Med Chem; 2018 Jun; 153():123-130. PubMed ID: 28732558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular phenotypes as inflammatory mediators in Parkinson's disease: Interventional targets and role of natural products.
    Jiang X; Ganesan P; Rengarajan T; Choi DK; Arulselvan P
    Biomed Pharmacother; 2018 Oct; 106():1052-1062. PubMed ID: 30119171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effects of angiotensin II interruption: evidence for antiinflammatory actions.
    Dagenais NJ; Jamali F
    Pharmacotherapy; 2005 Sep; 25(9):1213-29. PubMed ID: 16164395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New role of insulin in anti-inflammation: not only dependent of glycemic control].
    Liu GH; Li J; Gao F
    Sheng Li Ke Xue Jin Zhan; 2011 Oct; 42(5):366-70. PubMed ID: 22242405
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.